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Abstract 
 
Recent literature has supported a relationship between vascular disease and its role in the 
progression of cognitive impairment. Previous studies have demonstrated that white matter 
inflammation (WMI) in the brain is a common pathological outcome following stroke. 
Moreover, WMI has been shown to be the strongest predictor of cognitive decline following 
stroke. Finally, previous work in our lab has demonstrated, using a rodent model of striatal 
stroke, that WMI is correlated with post-stroke cognitive impairment. The current study aimed to 
further investigate the role of WMI in post-stroke cognitive impairment by utilizing a 
mediodorsal thalamic (MD) stroke model in the rat as well as a rat model of focal white matter 
inflammation. MD stroke in the mediodorsal thalamus was produced using an injection of the 
potent vasoconstrictor endothelin-1. Focal WMI was produced using injections of 
lipopolysaccharide into the corpus callosum. Behavioural flexibility was assessed using an 
operant set-shifting task to examine executive function, followed by post-mortem 
immunohistological analyses to assess WMI. We found that unilateral MD stroke produced a 
regressive behavioural phenotype, however no WMI was observed. Additionally, it was found 
that LPS-injected rats did not display traditional measures of behavioural inflexibility, however 
impairment was observed when assessing group error rates using a logarithmic regression model. 
The MD stroke model findings suggest that young rats may be more resilient to WMI than older 
rats. Additionally, the LPS model findings suggest that WMI may be implicated in causing 
executive dysfunction. Finally, this suggests a potential implication for anti-inflammatory 
treatment in the attenuation of cognitive impairment. 
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1.1 Stroke in Canada 
Stroke is the third most frequent cause of mortality in Canada 1. In 2013, a total of 741,800 
Canadians had experienced a stroke or were living with the effects of a previous stroke, and 
57,040 Canadians died from a stroke 1. Many factors can increase the risk of stroke, including 
hypertension, smoking, diabetes, dyslipidemia, obesity and atrial fibrillation 2–5. A person’s risk 
of suffering a stroke also increases rapidly with age, making it a significant health issue given the 
increasingly aging population in Canada 1. More recently, a trend towards decrease incidence of 
stroke has been observed, likely due to the increase in awareness of risk factors associated with 
stroke 1. For example, prevention efforts commonly include maintaining aspects of a healthy 
lifestyle including having a healthy diet, regular exercise regimen, avoiding alcohol and 
smoking, and controlling certain physiological conditions such as hypertension. Despite this 
recent decrease in incidence, better understanding of the molecular mechanisms of stroke 
damage is still required to improve recovery post-stroke.  
 
1.2 Overview of stroke types 
There are two major categories of stroke: hemorrhagic and ischemic. Hemorrhagic strokes 
occur when blood is released into the brain as a result of a vessel rupture within the brain and 
accounts for approximately 13% of observed strokes. The released blood causes an increase in 
pressure and damage to the affected brain region 6. Alternatively, ischemic strokes occur when a 
blockage of a cerebral blood vessel results in hypoperfusion, or complete blockage, of blood to 
an area of the brain, causing hypoxia, hypoglycemia and neurodegeneration in that region 7. 
Ischemic strokes are much more prevalent, accounting for approximately 87% of all observed 
strokes 8. There are three sub-classifications of ischemic stroke. The first type is thrombotic, 
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which is mainly caused when an atherosclerotic process initiates the formation of a thrombus at a 
particular location along the vessel, restricting blood flow to downstream vessel branches and 
brain structures. Other causes of thrombotic stroke include trauma or hemostatic 
disorders/disturbances 9. Another type of ischemic stroke is embolic stroke, in which a blood clot 
is formed in a different region of the body, such as the heart or extremities, and subsequently 
travels through the vasculature into a cranial artery where it becomes lodged, thus restricting 
blood flow past that point 10. Embolic strokes are more likely to occur in individuals with atrial 
fibrillation, as this condition causes a thrombus to form within the heart, which could be 
transferred into the cerebral vasculature 11. The last subtype is the lacunar stroke, which is not 
specified based on the process of vessel blockage, but rather the size of the vessel it affects. 
When an infarct occurs in a small vessel within the brain, it is called a lacunar stroke. A lacunar 
stroke accounts for approximately one quarter of ischemic strokes and it affects structures that 
are found deep within the brain, such as the basal ganglia, thalamus, internal capsule and 
brainstem 12,13. Lacunar strokes are also known as “silent strokes” since they may not elicit a 
clinically appreciable response upon occurrence but can cause very subtle deficits that 
accumulate over time 14. Risk factors for lacunar stroke include diabetes, smoking and 
hypertension 15. Conversely, cardiologic diseases such as atherosclerosis and atrial fibrillation 
are not risk factors for lacunar stroke as the etiology of lacunar strokes is not the same as the 
typical thrombotic and embolic stroke15,16. Additionally, the occurrence of a lacunar stroke 
increases the risk that a subsequent stroke will occur and it also increase the risk for post-stroke 
cognitive impairment 14. Given the associated risk of lacunar stroke and cognitive impairment, 
work in this thesis will focus on a pre-clinical model of lacunar stroke. 
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1.3 Pathophysiology of ischemic stroke 
The cellular events that occur following an ischemic stroke play a large role in the 
progression of cerebral damage (Figure 1.1) 17. When perfusion to an area of the brain is initially 
reduced there is a specific inner core region that experiences severe ischemia. Following 5-10 
minutes without adequate perfusion, this ischemic region becomes necrotic as the composing 
neurons and glia die due to excitotoxicity 10. Outside this core region is an area that experiences 
less severe ischemia due to small amounts of supportive collateral blood supply. This region, 
called the penumbra, may still maintain viability if appropriate therapeutic measures are 
delivered in time 18. In this region, cells can initiate apoptosis through the intrinsic apoptotic 
pathway, extrinsic apoptotic pathway and various other sequences that ultimately result in cell 
death 10.  
 In the acute phase following a stroke (minutes to hours), cells that experience hypoxia 
initiate a complex cascade of processes that involve effects ranging from cellular communication 
to structural changes in the tissue 19. Brain tissue can become damaged when it is no longer 
receiving oxygen, resulting in a depletion of ATP. Brain tissue can also be damaged if it 
undergoes a period of hypoxia and is rapidly reperfused. When cells become damaged, they lose 
membrane ion transporter function, causing a disruption in the ionic gradient 20. This results in 
cytotoxic edema resulting in increased permeability of cerebral blood vessels, which causes an 
influx of large serum proteins that draw in water 20.  
 The progression of cellular death can also occur when damaged neurons begin to release 
excitatory neurotransmitters such as glutamate and aspartate. These neurotransmitters can over-
activate N-methyl-D-aspartate (NMDA) and a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic  
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acid (AMPA) receptors, causing enzymatic dysregulation resulting in subsequent cellular 
degradation 21. In addition to excitatory neurotransmitters, damaged cells also produce reactive 
oxygen species (ROS) and free radicals, both of which induce cellular damage and initiate 
apoptosis. The production of ROS also result in the activation of matrix metalloproteases 
(MMPs), which alter the structural integrity of the brain by breaking down the blood-brain 
barrier (BBB) 22. In the acute phase, this is specifically accomplished by MMP-9 23.  
 Ischemia can be further exacerbated through vascular dysregulation and nitric oxide 
species (NOS) production. Following ischemia, endothelin receptors are upregulated 24. 
Endothelin is a mediator of vascular smooth muscle contraction leading to vasoconstriction, 
reducing perfusion to the ischemic area 24. This process may be counteracted with vasodilation 
caused by NOS released from ischemic induced endothelial cells. Conversely, neurons and 
immune cells in the ischemic area will also produce NOS, but this product will exacerbate 
cellular damage when produced from these cell types by increasing levels of ROS 25. 
Neuropeptides are also upregulated post-stroke and play a role in ROS production and vascular 
dysregulation. For example, increases in Substance P post-stroke results in additional 
inflammatory cytokine upregulation and free radical release, but it also promotes vasodilation 
through the promotion of NOS from endothelial cells 26. Neuropeptide Y also causes an increase 
in the production of NOS from endothelial cells and neurons 10. Altogether, vascular 
dysregulation and increases in neuropeptide release all increase ROS production, further 
exacerbating brain damage in the ischemic area.  
Inflammation plays a critical role in the pathogenic processes of stroke. Injured cells 
affected by ischemia produce inflammatory mediators such as cytokines and chemokines, which 
recruit additional immune cells to potentiate the inflammatory response. These inflammatory 
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mediators are released by neurons, endothelial cells within vessel walls or primarily glial cells 
such as astrocytes and microglia. Proinflammatory cytokines produced by these cells include 
interleukin-1 (IL-1), tumor necrosis factor- α (TNF- α) and high mobility group protein-1 (HMG-
1) 27–29. Proinflammatory cytokines and chemokines are upregulated post-stroke with the purpose 
of attracting additional peripheral immune cells into the brain. These include interleukin-8 (IL-8) 
for neutrophil recruitment, monocyte chemoattractant protein-1 (MCP-1) for monocyte 
recruitment, CC chemokine ligand-5 (CCR5) and regulated on activation normal T-cell 
expressed and secreted (RANTES) 27,30,31. All together the upregulation of these pro-
inflammatory molecules potentiate the current inflammation that occurs post-stroke.  
  Some anti-inflammatory compounds are also produced in the acute phase following a 
stroke. These include transforming growth factor-β (TGF- β) and interleukin-10 (IL-10) 32,33. 
Other neuroprotective factors produced during the acute phase are heat shock protein-70 (HSP-
70), B-cell lymphoma-2 (Bcl-2) family proteins, prion protein (PrPc), neurotropin-3 (NT-3) and 
granulocyte-colony stimulating factor (G-CSF) 34–37. These anti-inflammatory mediators are 
important for the initial control of the inflammatory response following a stroke.  
 In the subacute phase (hours to days) following a stroke, cells of the immune system 
begin to play a significant role in post-stroke inflammatory processes. Pro-inflammatory 
mediators produced in the subacute phase will initiate the upregulation of cellular adhesion 
molecules (CAMs) such as intercellular adhesion molecule-1 (ICAM-1) and vascular adhesion 
molecule-1 (VCAM-1) 38,39. These molecules allow circulating peripheral leukocytes to attach to 
the endothelium of the vasculature and subsequently infiltrate into the adjacent cerebral tissue 40. 
The introduction of these immune cells will allow for further propagation of inflammatory 
mediators and MMP activation. The production of various vascular growth factors by the newly 
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infiltrated immune cells helps to create angiogenesis in response to the brain damage that has 
been caused 41.  
  In the chronic period after a stroke has taken place (days to months), the inflammatory 
mediators cause upregulation of apoptotic gene expression 42. Harmful processes subside due to 
the removal of cell debris, the production of anti-inflammatory factors and the production of pro-
survival and growth factors 43,44. Cell debris removal is accomplished by microglia and 
infiltrating macrophages 45,46. Anti-inflammatory factors such as TGF-β and IL-10 are produced 
by microglia and regulatory T-cells, respectively 32,47. Lastly, neurons, microglia, astrocytes and 
other inflammatory cells all participate in repair by producing growth factors such as insulin-like 
growth factor 1 (IGF-1) and vascular endothelial growth factor (VEGF) in order to promote 
neuron sprouting, neuron regeneration, angiogenesis, etc. 48–51. Ultimately, the inflammatory 
components involved in the chronic phase following a stroke are focused on repairing damaged 
tissue and developing a scar around the affected area 52,53. 
 
1.4 Astrocyte response post-stroke 
Astrocytes have a critical role in maintaining neuronal health and are required for neuron 
survival. Part of the blood-brain barrier (BBB) is formed by astrocytic processes that form tight 
junctions with capillaries in the brain 54. The proximity of these processes to cerebral capillaries 
create an important role for astrocytes for water balance within the brain. When edema occurs 
following a stroke, these processes are the first to become edematous as they contain a large 
amount of aquaporins that allow for water regulation 55,56. Within hours following a stroke 
‘reactive astrogliosis’ occurs, meaning astrocytes become hypertrophic and proliferate at the site 
of damage 57. These cells are more protected, relative to neurons, in the setting of ischemia as 
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they are not impacted by glutamate cytotoxicity and are generally more adaptive during hypoxia 
58,59. Reactive astrocytes will also upregulate structural proteins such as glial fibrillary acidic 
protein (GFAP), which is a critical component of the astrocyte cytoskeleton and is also thought 
to be involved with signalling and cellular behhkaviour in periods of stress 60. In the acute setting 
to days following a stroke, these reactive cells can produce cytokines, chemokines and 
interferons 61–64. Reactive astrocytes are also involved in the healing process following a stroke 
and form a ‘glial scar’ surrounding the damaged area of the brain. This scar is created with 
intertwined astrocyte processes, GFAP, collagen and proteoglycans and it blocks regenerating 
axons 65,66. MMPs are also produced by reactive astrocytes, which contribute to BBB 
remodelling and repair 67,68. Lastly, astrocytes also assist with neurite growth and neurogenesis 
via the production of trophic factors such as IGF-1 and ciliary neurotrophic factor (CNTF) 57. 
Overall, astrocytes have a critical role in propagating an inflammatory response following a 
stroke and continue to participate in scar formation and neural repair long after an ischemic 
event. 
 
1.5 Microglia response post-stroke 
 Microglia play a critical role in the brain following a stroke, but the various presentations 
of these cells cause their role in stroke pathophysiology to be complex. In the healthy brain, 
microglia function to survey the brain environment 69. Following stroke, inflammatory mediators 
such as monocyte chemoattractant protein-1 ( MCP-1) are released from degenerating neurons 
which act as chemoattractants for microglia recruitment to the ischemia region 70,71. Following 
recruitment, microglia generally show characteristics of an M1 or M2 phenotype. The activation 
status is complex and relies on a variety of factors, but mostly depend on the timing post-stroke. 
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72. M1 microglia are recruited early to the ischemic site post stroke and play a role in pro-
inflammatory processes. by releasing ROS, NOS and proinflammatory cytokines such as IL-1, 
TNF-a and interleukin-6 (IL-6); all of which cause neuronal death 73,74. They also produce 
MMPs that further contribute to the destruction of the BBB resulting in subsequent leukocyte 
infiltration. Alternatively, M2 microglia are considered anti-inflammatory as they release anti-
inflammatory cytokines and mediators such as TGF-b, VEGF and IL-10 39,75–77. M2 microglia 
are recruited later in the post-stroke process and play a role in tissue repair and angiogenesis 76,77. 
Overall, microglia can serve drastically different functions over the post-stroke period and are 
critical to both the damage and repair that occurs. 
 
1.6 White matter 
 The brain is composed of both grey matter and white matter. Grey matter comprises the 
cell bodies of neurons, along with their axon terminals and dendrites. White matter contains the 
axons of neurons which form tracts to form the connection between grey matter structures 
allowing for communication between areas of the brain 78. Axons within the white matter are 
surrounded by myelin, a lipid-rich substance that provides electrical insulation to axons, allowing 
for faster conduction of action potentials. In the central nervous system (CNS), myelin is 
produced by oligodendrocytes 79. There are three overarching categories of white matter tracts: 
(1) projection fibers, (2) association fibers and (3) commissural fibers, which each serve a 
different function 78. Projection fibers connect subcortical areas of the brain to areas within the 
cortex, while association fibers connect regions of the cortex to other areas within the ipsilateral 
hemisphere 78. Finally, commissural fibers connect corresponding areas of the ipsilateral and 
contralateral hemispheres 78. 
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White matter is disproportionately hypoperfused in comparison to grey matter and is thus 
highly susceptible to damage when exposed to reduced blood flow 80. Energy metabolism in 
axons occurs independently from neuron cell bodies, therefore, if energy supply is disrupted at 
any point along the axon due to hypoperfusion, axon viability may be compromised 12. 
Moreover, axonal degeneration can occur without any damage to their neuronal cell body 81,82. 
Damage to the white matter caused by pathological processes including stroke reduces the 
functionality of white matter circuitry, as the transmission of action potentials is disrupted, which 
may have negative cognitive outcomes to the affected individual 83.  
 
1.7 White matter inflammation 
A commonly identified pathological outcome following a stroke is the onset of 
neuroinflammation. White matter is hypoperfused relative to grey matter, which may contribute 
to its vulnerability to hypoxia and the resulting inflammatory response that leads to ischemic 
injury 84–86. As previously mentioned, damage and necrosis of brain tissue occurs following 
stroke as a result of a robust inflammatory reaction marked by production of inflammatory 
cytokines, passage of peripheral immune cells through the disrupted BBB and activation of 
microglia and astrocytes. Due to the hypoperfusion of white matter, oligodendrocytes and 
progenitors are very susceptible to the effects of inflammation caused by stroke, and this leads to 
continued inflammation within the white matter following ischemia 87. Approximately 95% of 
stroke infarcts affect white matter to some degree, and on average, half of the volume of these 
infarcts is in white matter locations 88. 
 Ischemic stroke has been shown to be a reliable cause of white matter inflammation 
(WMI) 84,85. WMI is extremely dynamic and has been shown to spread to remote areas of the 
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brain following a stroke 81,89. For example, in one clinical study investigating a positron emission 
tomography (PET) marker for activated microglia, which is used as an indicator of inflammation, 
it was found that white matter inflammation was seen not only at the point of injury, but also in 
remote white matter areas of the brain where it continued to persist 6 months following stroke 90. 
Furthermore, there is evidence that remote degeneration from an acute ischemic infarct is 
facilitated through connecting white matter tracts 91,92. Therefore, an ischemic stroke appears to 
cause WMI that can propagate to distant regions via white matter structures. 
  In addition to WMI produced by cerebral injury, levels of WMI will also increase as an 
individual ages and may be related to a chronic state of hypoperfusion 93. WMI is an identified 
risk factor for stroke and it strongly affects the outcome of an individual when a stroke has 
occurred 94. In terms of the damage elicited by a stroke, infarct volumes are larger when WMI is 
present at baseline prior to a stroke 95–97. The presence of WMI prior to a stroke also increases 
the functional deficits caused by a stroke and a greater extent of inflammation will exacerbate 
these effects further 94,95,98. Most importantly, the extent of WMI has been shown to be the 
strongest predictor of post-stroke cognitive impairment 84,99. For example, the prognosis of a 
stroke patient is greatly affected by preceding WMI, as it is indicative of an unfavourable 
recovery at three months following a stroke and a greater rate of mortality at one year post-stroke 
100–102. One potential explanation for the negative impact of WMI is the fact that it can alter the 
structure and function of white matter bundles, likely disturbing the processes involved with 
plasticity and repair following a stroke 103,104. 
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1.8 Cognitive impairment and executive function 
Recent literature has strongly supported a relationship between vascular disease and the 
progression of cognitive impairment 105–108. Cognitive deficits observed following stroke can be 
diverse depending on the brain areas impacted by the injury; and this phenomenon has been 
demonstrated in pre-clinical models of stroke. For example, when a stroke was induced within 
the motor cortex, rats demonstrated difficulties in completing tasks that require intact motor 
capabilities. Whereas when a stroke was induced within the hippocampus, rats demonstrated 
impairments in spatial learning and memory 109,110. 
A key aspect of cognitive decline post-stroke involves impairment in executive function  
111. Executive functions includes higher order processes such as planning, rule discovery, 
behavioural flexibility and working memory 112, all of which rely on intact white matter 
connectivity 113,114. Injury to these white matter tracts that connect key brain regions can be 
detrimental to the proper functioning of the circuitry and their gray matter targets. Animal 
models of focal ischemic stroke targeting specific grey matter structures have been able to 
reliably produce cognitive impairment in the form of executive dysfunction (ED) 115,116. For 
example, previous experimental work has explored the effects of small striatal infarcts on WMI 
and executive function. Interestingly, results showed that rats with the greatest amount of 
inflammation (as denoted by activated microglia) in frontal white matter structures displayed the 
greatest degree of behavioural inflexibility, a correlate of ED (preliminary data). This, together 
with clinical evidence, suggests that WMI and ED may occur concomitantly. 
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1.9 Behavioural flexibility as a measure of executive function 
 A component of executive function often disrupted following stroke is behavioural 
flexibility, which is defined as the ability to alter behaviour in response to changing 
environmental stimuli 117. It involves a number of higher order functions including generating 
novel behavioural strategies and maintaining these strategies while suppressing the use of 
previously successful strategies 118. Behavioural flexibility, along with the other domains of 
executive function, depends highly on the integration of multiple brain structures, which relies 
on functional white matter connectivity 113,114. Behavioural flexibility has been commonly 
assessed clinically using the Wisconsin Card Sorting Task (WCST) 117. Using animal models of 
disease to assess clinical questions in humans presents a need to develop adequate behavioral 
testing paradigms for behavioural flexibility in animal models. 
 There have been several tests of ED that incorporate aspects of behavioural flexibility for 
rodents. Through the use of these tests, the neural circuitry mediating behavioural flexibility has 
been identified using pharmacological inactivation approaches, and are comprised of the 
prefrontal cortex (PFC), nucleus accumbens (NAc) and mediodorsal thalamus (MD) 118 (Figure 
1.2). Circuitry connecting the PFC and MD have been shown to regulate strategy shifting from 
an old to new paradigm 118. Damage to this circuitry in rats resulted in impairments in the ability 
to switch to a new strategy indicated by perseverative behaviours 118. Circuitry connecting the 
MD to the NAc is shown to be involved in regulating the use of unrewarding or inappropriate 
strategies 118. Damage to this connection in rats resulted in an increase in strategy exploration 
and ‘guessing’ errors 118. Finally, PFC and NAc circuitry is associated with maintaining the use 
of a novel strategy 118. Circuitry disruption in rats resulted in regressive behaviours whereby rats 
demonstrated inability to maintain the new strategy regressing to the previous strategy118.  
 15 
 
 
 
 
 
 
 16 
Selectively damaging a specific component of this well-defined circuitry allows researchers to 
delineate the role that structure plays in executive function, and how it can be affected following 
injury such as stroke. Thus, modern rodent tests of behavioural flexibility can provide valuable 
insight into possible mechanisms of ED that can be further explored in humans. 
 
1.10 Rodent models of ischemic stroke 
There is a considerable need to create reliable and accurate models of ischemic stroke in 
order to delineate its mechanistic properties, pathophysiology, and possible interventions in a 
controlled environment 119. To accomplish this, rats are often employed largely due to their 
similarities with humans in terms of their cerebrovasculature 120. Furthermore, rats are a 
relatively less costly model that can be easily manipulated to create highly reproducible strokes 
with predictable post-stroke behavioural outcomes. 121.  
 There are a wide variety of ischemic stroke models produced in rats, each with their own 
benefits and disadvantages. While there are several models of hemorrhagic stroke including 
decapitation and cardiac arrest, among others, these models produce whole-brain ischemia and 
are thus unable to be used to investigate the effects of ischemic stroke targeting specific areas of 
the brain 122,123. Other models, however, allow for focal ischemia to be produced in the brain. For 
example, the most commonly used focal method is the middle cerebral artery occlusion (MCAO) 
model 124. While this can be accomplished through a craniectomy with surgical occlusion of the 
vessel, this is extremely invasive, and so it is more commonly accomplished using an 
intraluminal suture 119,125. In this method, an intraluminal suture is inserted and used to obstruct 
blood flow within the middle cerebral artery to produce ischemia 126. This can be done 
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permanently or transiently in order to study the effects of reperfusion. While this method is quite 
commonly used, it carries with it a greater risk for vessel rupture as well as hyperthermia 127,128. 
Ischemic stroke have also been modelled using emboli either through the injection of thrombi 
from the animal itself, or artificial thrombi composed of materials such as collagen 129 or 
polyvinylsiloxane 130 to produce ischemia 119. As human strokes are most commonly produced 
by emboli, this model shares a similar origin of ischemia making it highly clinically relevant 131. 
This model, however, possess a greater risk of mortality and can produce inconsistent infarcts 
132. Photothrombosis is a less surgically invasive ischemic stroke model 133. Following the 
intravenous (IV) injection of photosensitive dye that is sensitive to a specific wavelength of light, 
a beam of light is exposed to a surface vessel initiating thrombosis within that area to ultimately 
produce ischemia 133,134. While this model provides many benefits such as low mortality rates 
and high reproducibility, it produces an infarct with no penumbra, making it less clinically 
relevant as well as less physiologically representative when used as a model to study 
pharmacological intervention 133,135. Finally, ischemic stroke is often modelled in animals using 
injection of the potent vasoconstrictor endothelin-1 (ET-1) to occlude blood flow of target 
vessels. The greatest vasoconstriction induced by ET-1 occurs at 60 minutes and attenuates to 
regular flow by the 3-hour mark 136. ET-1 can be applied to external vessels or can be injected 
focally allowing for investigation of the effects of stroke on distinct brain regions. It produces 
highly reproducible lesions and is associated with lower mortality rates, while not producing 
physiological or outwardly apparent stress in the animal 137–139. This model would not be useful 
for studying the mechanisms of neuron repair, as ET-1 can promote axonal sprouting 140. 
Additionally, there is a gradual decrease in vasoconstrictive properties over time, so ET-1 lacks 
precise control over reperfusion time 137. While no animal model can fully recapitulate the 
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complete physiological mechanisms involved in stroke in humans, they each provide a unique, 
less-invasive approach for researchers to investigate critical processes and interventions that 
could translate to human studies and stroke treatment.  
 
1.11 Rodent models of WMI 
WMI is a key feature of stroke and plays a critical role in post-stroke cognitive impairment. 
Currently, our understanding on the specific role of WMI with respect to its associative or causal 
role in post-stroke cognitive impairment is poorly understood. This is due, in part, to a lack of 
pre-clinical models of focal WMI. Systemic inflammation caused by peripheral injection of 
inflammatory stimulants or peripheral injury can lead to inflammation within the brain. Systemic 
inflammation can be induced in animals by cardiac arrest 141, liver failure 142, acute pancreatitis 
143 or burns 144,145. Systemic inflammation can also be induced by injections of 
lipopolysaccharide (LPS), an immunogenic component of the gram negative bacterial cell wall, 
into the vasculature 146,147. Although these models produce a wide-spread brain inflammation, 
including within the white matter, a more refined model that selectively targets the white matter 
tracts is still needed to assess the consequences of white matter inflammation on cognitive 
decline.  
  Techniques to induce a more focal WMI within the brain are more limited. One method 
to induce focal inflammation within the brain is by injection of viruses producing small 
interfering ribonucleic acid (siRNA). In response to these injections, the brain mounts an 
inflammatory response to the siRNA as it would to invading viral double-stranded ribonucleic 
acid (dsRNA) 148. This technique is still in its infancy and therefore does not have sufficient 
supportive studies. The most utilized technique of focal WMI induction is via the injection of 
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LPS. Previous studies have shown that LPS mounts an appropriate inflammatory response within 
targeted regions of the brain by increasing levels of TNF-α, IL-1, IL-6 and iNOS (inducible nitric 
oxide synthase) 149–152. Consequently, this also resulted in the recruitment and activation of 
astrocytes and microglia and promoted the infiltration of systemic monocytes and neutrophils 
into the brain 149,150,153. Inflammation and demyelinating damage caused by the LPS injection has 
also been shown to propagate and spread along white matter connections from a focal initiation. 
Thus, intracerebral LPS injections have been demonstrated to be a reliable model to study the 
effects of producing focal inflammation in the brain. 
  
1.12 Rationale, objective, and hypothesis – Aim 1 
Clinically, activated microglia persist chronically within the white matter 90 and are a 
strong predictor of cognitive impairment post-stroke 84,99. These findings have also been 
recapitulated in our lab where unilateral subcortical ischemia in the striatum induced long-lasting 
bilateral WMI in frontal white matter structures such as the corpus callosum. Additionally, these 
animals displayed impaired executive function in the form of a regressive behavioural 
phenotype. This WMI was positively correlated with ED whereby rats with the greatest amount 
of WMI was the most impaired when assessed behaviourally (unpublished data).  
To further investigate the underlying role of WMI in cognitive decline, work in this thesis 
aimed to assess if WMI and ED could be a consequence of focal stroke in the MD. This region 
was chosen since it is part of the same circuitry as the dorsal striatum, the site of focal stroke in 
previous studies. The MD is also a common target of small vessel (lacunar) infarcts 154, is well-
connected to the prefrontal cortex and plays a critical role in executive function 155. Finally, 
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clinical studies have shown that stroke targeting the MD impairs the MD, dorsal striatum, PFC 
circuitry resulting in impairments in executive function 156,157.  
We hypothesized that white matter inflammation post-stroke will correlate with 
impairments in behavioural flexibility. Additionally, we evaluated the outcomes following either 
unilateral or bilateral stroke. We further hypothesized that rats with bilateral MD stroke will 
show greater white matter inflammation than animals with a unilateral MD stroke resulting in 
strong levels of behavioural inflexibility.  
 
1.13 Rationale, objective, and hypothesis – Aim 2 
 
To date, research in our laboratory has demonstrated a correlative link between WMI and 
behavioural inflexibility, a measure of ED. It is unclear whether the inflammation within the 
white matter tracts causes, or is simply associated with, the observed behavioural inflexibility. 
Therefore, the second of AIM of this thesis was to establish whether selective white matter 
inflammation induced by LPS injections into the corpus callosum (CC) result in impairments in 
behavioural flexibility. We hypothesize that white matter inflammation is sufficient to cause 
impairments in behavioural flexibility. Lipopolysaccharide, or LPS, is a cell wall component of 
gram-negative bacteria, and it has been well-established using both systemic and focal injections 
as a model of producing neuroinflammation 146,147,149–153. Additionally, LPS injections have been 
shown to produce significant inflammation in the white matter 149–153. In comparison to WMI 
seen in animal models of stroke that could have a number of confounding factors aside from 
inflammation contributing to cognitive impairment, this would produce a pure model of WMI 
that will allow us to determine whether white matter inflammation is causative of cognitive 
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impairment. The CC was chosen as the site of LPS injection because it has been found that 
animals with the most inflammation in anterior white matter structures such as the CC, they were 
the most impaired in the set-shifting task, giving us an effective area to target to see if WMI can 
cause ED (unpublished data). 
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Section 2: METHODS 
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2.1 Animals 
All animal use and procedures were in accordance with the Canadian Council on Animal 
Care and approved by the Animal Care Committee at Western University (Protocol 2014-016). 
Sixty 6-month male homozygous wildtype (WT) Fischer 344 rats were used in total for 
experiments in Aims 1 and 2. Rats were bred and aged, housed in pairs within the Animal Care 
and Veterinary Services at Western University and kept on a 12:12 hour light/dark cycle 
alternating at 1 AM/PM. Behavioural testing always occurred during the dark cycle. 
 
2.2 Endothelin-1 focal ischemia model 
Focal cerebral ischemia was accomplished using an injection of the potent vasoconstrictor 
endothelin-1 (ET-1) into the subcortical mediodorsal thalamus (MD). This stroke model has been 
shown to produce small lacunar infarcts that are commonly observed clinically in precise targets 
that are highly reproducible 137,138. When injected, ET-1 induces focal ischemia of the 
surrounding vessels with the greatest vasoconstriction induced at 60 minutes and attenuates to 
regular flow by the 3-hour mark 136. Prior to surgery, rats were injected subcutaneously with 0.03 
mg/kg buprenorphine diluted in 0.9% sterile saline. ET-1 was dissolved in sterile saline to a 
concentration of 10 pmol per 1 µL. ET-1 was stored at -80 °C in 10 µL aliquots. Rats were 
chosen at random to receive either a unilateral injection of ET-1 into the right MD or a bilateral 
injection of ET-1 into the left and right MD, (AP -2.9, ML ±0.7, DV -5.3) using a 32-guage 
Hamilton syringe (Hamilton Company, Reno, NV, USA, n=10 for all groups, 1 µL volume per 
injection). Following injection, rats were given an intramuscular injection with 0.03 mL of 
Baytril (Bayer Inc., Toronto, ON, Canada). Controls underwent an identical surgical procedure 
with the exception of receiving either a unilateral injection of 1 µL saline into the right MD, or a 
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bilateral injection of 1 µL saline into both the left and right MD. A 15% post-surgery (24-hours) 
mortality rate and a 6% mortality rate during the 28-day post-surgery period before euthanasia 
was observed. 
  
2.3 Lipopolysaccharide injections 
 Lipopolysaccharide (LPS) is a component of the cell wall of gram-negative bacteria, and 
produces neuroinflammation following systemic or focal injections 146,147,149,150,153,158. Prior to 
surgery, rats were injected subcutaneously with 0.03 mg/kg buprenorphine diluted in 0.9% sterile 
saline. LPS was dissolved in sterile saline to a final concentration of 5 µg/1 µL. LPS was stored 
at -80 °C in 10 µL aliquots. Rats were chosen at random to receive either a bilateral injection of 
LPS into the left and right CC (AP +1.2, ML ±1.8, DV -3.0) or control injections of saline using 
a 32-guage Hamilton syringe (Hamilton Company, Reno, NV, USA, n=10 for all groups; 2 µL 
volume per injection). Following injection, rats were given an intramuscular injection with 0.03 
mL of Baytril (Bayer Inc., Toronto, ON, Canada). A 9% post-surgery (24-hours) mortality rate 
and 4% mortality rate during the 28-day post-surgery period before euthanasia was observed. 
 
2.4 Behavioural Testing 
2.4.1  Strategy set-shifting 
 After a 21-day recovery period following surgery, rats were assessed using a strategy set-
shifting task where rats were required to shift from a visual cue strategy to a location-based 
response discrimination strategy 159. One rat was omitted from results due to an inability to 
complete this task. 
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2.4.1.1 Food restriction 
 During the pre-testing period, rats were given ad libitum access to both food and water. 
Food restriction was initiated 6 days prior to the testing period. Prior to restriction, rats were 
weighed, and the pre-restriction weight was recorded. Pair-housed rats were then restricted to a 
target weight of approximately 85% of their initial weight in order to motivate them to fully 
participate in the food-motivated testing. Rats were weighed every second day for the remainder 
of the testing period. Water continued to be provided freely. For 2 days prior to testing, rats were 
provided with approximately ten sucrose pellets each day in order to familiarize them with the 
food rewards that would be used in testing. 
 
2.4.1.2 Apparatus 
Rats were placed in one of two sound-attenuating chambers with retractable levers in front of 
them on either side of the chamber, each with a stimulus light above them (Figure 5). Rats were 
tested in the same box for the duration of the experimental period. A food hopper was present in 
the middle of the two levers to provide food rewards. A house light was located at the back of the 
chamber. All testing was completed using the program MED-PC (Med Associates, VT, USA). 
This program allowed for automated control of all components of the experimental procedure. 
All procedures were recorded using a portable camera mounted to the roof of the chamber 
(Grand & Toy, Canada). Testing was performed at the same time in the dark cycle daily until 
completion of all testing. 
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2.4.1.3 Training 
 One day prior to the initiation of training, rats were placed in the testing apparatus for 20 
minutes to habituate them to their testing surroundings. On the first training session, rats were 
manually trained to lever press using operant conditioning to form an association between lever 
pressing and the pellet reward. In this non-automated training task, I had full control over 
retractable lever movement and pellet dispensing. Successful task completion required the rat to 
press the left lever 15 times, the right lever 15 times, and finally 15 alternations between the left 
and right levers. 
 The following day, rats completed a fully automated training procedure used to ensure 
they could reliably lever press and had the capability to do so for the entirety of the testing 
period. Rats began this training session in the dark chamber with both levers retracted. A trial 
began once the house light illuminated to reveal an extended lever, at which time the rat would 
have ten seconds to respond by pressing the lever. During these trials, each lever was presented 
in a counterbalanced manner, with each being presented 50% of the time. If the rat responded 
correctly, they would receive one 45 mg banana-flavoured sucrose pellet (Dustless precision 
pellets, Bio-Serv, NJ, USA) from the food hopper immediately following lever pressing. The 
house light would then remain illuminated for 3 seconds. If the rat failed to respond an omission 
was recorded and the house light went out immediately and no food reward was received. This 
training session consisted of 90 trials, with a 20 second inter-trial period. Successful completion 
consisted of scoring five or fewer omissions throughout the task.  
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2.4.1.4 Side bias determination 
 Following successful completion of training, the side bias (left or right) of each rat was 
determined. At the initiation of the first trial both levers were extended and the rat received a 
pellet for responding on either lever. Following the inter-trial period, both levers were presented 
once again and the rat was required to respond on the opposite lever to receive an award. Seven 
lever alternation trial pairs were completed in this task. If a rat pressed one lever at least twice as 
many as the other, this was said to be the rat’s side bias. If this did not occur, the lever that was 
chosen first in at least 60% of the presentations was chosen.  
 
2.4.1.5 Visual cue discrimination testing 
 In the visual cue discrimination (VD) task, rats were trained to associate an illuminated 
stimulus light positioned over one of the levers with receiving a food reward. VD testing took 
place 24-hours following completion of side bias determination. At the beginning of each of the 
100 trials, the house light was illuminated for three seconds, followed by extension of both levers 
and illumination of the stimulus light above one of the levers. In order to receive a food reward, 
the rat was required to press the lever corresponding to the illuminated stimulus light within the 
10 second trial period, and the house light would remain on for an additional 3 seconds. If the rat 
selected the lever without an illuminated stimulus light, they would receive no reward, the levers 
would retract, and the house light would turn off immediately. Finally, if the rat failed to respond 
at all in the 10 second trial, no reward would be provided, the house light would turn off, and the 
trial would be scored as an omission. During these trials, the stimulus light was illuminated over 
both levers in a counterbalanced and randomized manner, with each being correct 50% of the 
time. The rat met the criteria for this task when they responded correctly on 8 consecutive trials 
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116,160. If this point occurred before the full 100 trials were complete, the rat would remain in the 
chamber to participate in the remainder of the trials. If the rat failed to meet the required criteria 
for this task, they were re-tested the following day. 
 
2.4.1.6 Response discrimination set-shift testing 
 Twenty-four hours following successful completion of VD testing, each rat was provided 
with 20 VD trials to ensure that the rat had properly internalized the visual cue strategy. 
Following completion of these trials, rats were assessed as to whether they can shift away from 
the previously successful visual cue strategy, to a novel response discrimination (RD) spatial 
strategy. The rat was presented with 120 trials for the response discrimination “set-shift” task. To 
receive reinforcement, the rat was required to ignore the illuminated stimulus lights and respond 
by pressing the lever on only the side opposite to their side bias. During these trials, the stimulus 
light continued to be illuminated over both levers in a counterbalanced and randomized manner, 
with each illuminated 50% of the time overall. The rat met the criteria for this task when they 
responded correctly on 8 consecutive trials 116,160. If this point occurred before the full 120 trials 
were complete, the rat would remain in the chamber to participate in the remainder of the trials. 
If the rat failed the meet the required criteria for this task, they were re-tested the following day. 
 
2.4.1.7 Response discrimination reinforcement 
Twenty-four hours following successful completion of RD testing, each rat was provided 
with an additional 120 RD trials where they were again required to press the lever on only the 
side opposite to their side bias. This was completed to ensure that the rat had successfully 
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internalized the response discrimination strategy. The rat met the criteria for this task when they 
responded correctly on eight consecutive trials. If this point occurred before the full 120 trials 
were complete, the rat would remain in the chamber to participate in the remainder of the trials. 
If the rat failed the meet the required criteria for this task, they were re-tested the following day. 
  
2.4.1.8 Intradimensional reversal testing 
 Twenty-four hours following successful completion of the additional RD testing day, 
each rat was given 20 RD trials to ensure that the rat had successfully internalized the location-
based strategy. Following completion of these trials, each rat was assessed as to whether they 
could perform an intradimensional “shift”, where they must learn to press the lever consistent 
with their side bias, and thus opposite to the side in which they were trained during the RD trials 
to receive a reward. The rat met the criteria for this task when they responded correctly on eight 
consecutive trials. If this point was never reached, the rat was said to be unsuccessful in this 
reversal testing, however, no further testing took place for any rats. 
 
2.4.1.9 Error analysis 
 While the ability to set-shift can provide important information, the true value of this task 
in examining executive function comes in the evaluation of individual error types involving the 
acquisition and maintenance of strategy use 159. There were three types of errors examined 
during the response discrimination aspect of the task. Perseverative errors involve an inability to 
shift away from the previous learned strategy. A perseverative error occurred when a rat 
continued to follow the light when the new spatial strategy was correct. Alternatively, regressive 
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errors occurred when a rat acquired the new spatial strategy, but then failed to maintain it 
reverting back to the original visual cue strategy. Finally, never-reinforced errors (NRE) 
occurred when a rat made a choice that was inconsistent with both strategies. For example, if the 
light was illuminated over the left lever, and the rat pressed the right lever, it would be 
considered an NRE. These errors are associated with exploration of new strategies. 
 
2.4.2  Morris water maze 
A modified version of the Morris water maze (MWM) training schedule was enlisted to 
assess spatial learning and memory in the rats used in the LPS experiment 161. Since the MWM is 
a hippocampal-dependent task, we did not expect to see any memory differences between the 
two groups, so this task was enlisted to serve as a control to ensure that memory was intact in 
both the control and experimental groups prior to testing executive functioning.  
 
2.4.2.1 Apparatus 
Testing involved rats being placed in a water tank (144 cm diameter) filled with water 
dyed with black non-toxic acrylic paint in order to eliminate visibility of the platform structure 
below the water. The water was kept at room temperature. The target platform (12 cm diameter) 
was placed in the tank and submerged below 3 cm of water. The “platform region” was 
designated as the area within 7.5 cm diameter from the edge of the platform. The tank was 
surrounded with black panels fixed with three large symbols for the rats to use in spatial 
navigation. This was done to prevent visibility of the room to ensure that the only external cues 
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the rats were using to navigate were the symbols provided. The room was kept dimly lit 
throughout the duration of testing. 
 
2.4.2.2 Learning trials 
 The first day of the MWM task consisted of six learning trials where the rat was required 
to use spatial cues in their environment in order to navigate to a platform hidden under 3 cm of 
water. This platform remained in a consistent location for the duration of all trials. Three large 
distal cues were placed around the pool to be used in the rat’s spatial navigation.  
At the beginning of each trial, the rat was placed in the pool facing backwards and 
allowed to search for the platform location for up to 90 seconds. If they didn’t successful locate 
the platform, they were guided to it by the experimenter. The rat was then left on the platform for 
30 seconds following each trial in order to give time for the rats to spatially map the cues around 
them to use to locate the platform. If the rat left the platform at any point before this 30 second 
period was complete, they were gently guided back to the platform and were left there until they 
remained on the platform for a full 30 seconds. This procedure continued until each rat had 
participated in six learning trials. Swimming location and additional parameters were recorded 
throughout all trials. 
 
2.4.2.3 Retention probe testing 
Twenty-four hours following the final trial of learning, the platform was removed from the 
pool. Each rat underwent a probe trial where memory for the prior platform location was 
assessed. The three distal cues were placed around the pool in the same location as the learning 
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trials to be used in the rat’s spatial navigation. At the beginning of the probe trial, the rat was 
placed in the pool facing backwards and allowed to swim freely for the 90 seconds duration of 
the trial. Swimming location and additional parameters were recorded throughout the trial. 
 
2.4.2.4 Visual cue testing 
 Following testing, rats were assessed using a visual cue task to ensure that their vision 
was intact. Any issues detected with vision would suggest that rats would not be able to properly 
complete the task by navigating using the external spatial cues provided. In the first component 
of this task, the platform was placed in the middle of the northeast (NE) quadrant of the tank 
with a salient object on top of it, allowing the rats to quickly locate the platform location. Rats 
were placed in the southeast (SE) quadrant of the pool facing backwards and allowed to search 
for the platform and salient object for up to 90 seconds. After the rat located the platform, they 
were immediately removed from the pool and placed back in the southwest (SW) quadrant of the 
pool facing backward and were allowed to search for the same platform and object location for 
up to 90 seconds. After successfully locating the platform, the rat was removed from the pool 
and allowed a 1-hour inter-trial rest period.  
 In the second component of visual cue testing, the platform was placed in the center of 
the northwest (NW) quadrant of the pool with a salient object on top of it. Again, rats were 
placed in the southeast (SE) quadrant of the pool facing backwards and allowed to search for the 
platform and salient object for up to 90 seconds. After the rat located the platform, they were 
immediately removed from the pool and placed back in the southwest (SW) quadrant of the pool 
facing backward and were allowed to search for the same platform and object location for up to 
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90 seconds. After successfully locating the platform, the rat was removed from the pool and 
testing was complete. 
 
2.5 Tissue Collection and Preparation 
 Following completion of behavioural testing, at 28 days post-surgery rats were 
euthanized by an intraperitoneal injection of sodium pentobarbital (48 mg/mL, Bimeda-MTC, 
Cambridge, ON). Rats were then perfused transcardially with 0.01 M phosphate buffered saline 
(PBS, pH 7.4) for 3 minutes followed by 4% paraformaldehyde (PFA) diluted in PBS for 7 
minutes. Brain tissue was extracted and then placed in 4% PFA for 24 hours, and then transferred 
to a solution of 30% sucrose diluted in double-distilled water (ddH2O) until used for sectioning. 
The brain was flash frozen on dry ice, sectioned coronally at 30 µm using a cryostat (CryoStar 
NX50, Thermo Scientific, MI, USA) and then stored in cryoprotectant at -20 ºC until processed. 
 
2.6 Thionin Histochemistry 
 Thionin histochemistry was used to assess cell loss as a result of stroke injury by staining 
for cellular nissl substance. Free-floating tissue sections were thoroughly washed in 0.01 M PBS 
to remove all cryoprotectant. Tissue sections were then mounted on SuperFrost Plus slides 
(VWR International, PA, USA) using 0.3% gelatin, and then allowed to fully dry over 24 hours. 
Mounted tissue sections were then rehydrated using decreasing concentrations of ethanol from 
100% to 50% followed by ddH2O. The tissue was then submerged in a solution of 0.5% thionin 4 
consecutive times and was then transferred to three ddH2O washes. The tissue was then 
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progressively dehydrated from 50% to 100% ethanol followed by clearance with xylene. Finally, 
slides were mounted using DePex mounting medium (DePex, BDH Chemicals, Poole, UK). 
 
2.7 Immunohistochemistry 
 Tissue sections were stained either with either OX-6 (OX-6, BD Pharmingen, 
Mississauga, Canada, 554926) as a marker for major histocompatibility complex II (MHC-II) to 
assess activated microglia, GFAP (GFAP, Sigma-Aldrich, Oakville, Canada, G3893) to assess 
reactive astrocytes, or neuronal nuclei (NeuN, Millipore-Sigma, Temecula, CA, USA, MAB377) 
as a marker for neuronal cell bodies. Free-floating tissue sections were thoroughly washed with 
0.01 M PBS in order to remove all remaining cryoprotectant. The tissue was then incubated in 
1% hydrogen peroxide for 10 minutes (15 minutes for NeuN). Tissue sections were then 
incubated at room temperature in horse serum blocking solution (Sigma-Aldrich, Oakville, 
Canada) for one hour, followed by incubation with primary antibody in blocking solution (OX-6: 
1:1000; GFAP: 1:500; NeuN: 1:000) at 4 ºC overnight. The following day, tissue sections were 
washed with 0.01 M PBS and the incubated in biotinylated horse anti-mouse secondary antibody 
in blocking solution (1:500, Vector Laboratories Inc., Burlingame, CA, USA) for one hour at 
room temperature. Tissue was then incubated in avidin-biotin complex solution (ABC 
Peroxidase Staining Kit, Thermo Scientific, Rockford, IL, USA) for one hour at room 
temperature. Tissue was then developed in a solution of 3-3-diaminobenzene tetrahydrochloride 
(DAB, Sigma-Aldrich, Oakville, Canada) in hydrogen peroxide. Tissue sections were then 
mounted on glass slides (VWR VistaVision Microscope Slides, VWR International, Radnor, PA, 
USA) and allowed to dry overnight. Slides were then dehydrated progressively from 50% 
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ethanol to 100% ethanol, cleared in xylene and mounted with DePex mounting medium (DePex, 
BDH Chemicals, Poole, UK). 
 
2.8 Microscopy Imaging and Analysis 
 Tissue sections were analyzed using a Nikon Eclipse Ni-E upright microscope with a 
Nikon DS Fi2 colour camera head (NIS Elements Imaging). The researcher was blinded to rat 
experimental condition to present bias during analysis. For OX-6, GFAP, and NeuN analysis, 
10x magnification images were used for image analysis. For OX-6 and GFAP, images of four 
tissue sections per rat per stain were taken to assess OX-6 and GFAP immunoreactivity. ImageJ 
(National Institutes of Health, Bethesda, MD, USA) was used to determine % coverage of OX-6 
and GFAP positive staining in the forceps minor (+ 3.00 from bregma) as well as in three 
different tissue sections of the CC (+1.92, - 0.48 and – 2.92 from bregma) in order to get a 
representative depiction of immunoreactivity throughout the brain. For NeuN, images of two 
tissue sections per rat were taken to assess Neu-N immunoreactivity in terms of cell number in 
the PFC (+ 3.00 from bregma) as well as the NAc (+ 1.92 from bregma). Sections of interest 
were identified using a rat brain atlas 162. 
 
2.9 Statistical Analysis  
 Statistical analyses were conducted using GraphPad Prism software (GraphPad, La Jolla, 
CA, USA). All figures were prepared using GraphPad Prism in addition to CorelDraw X7 
software (Corel, Ottawa, ON, Canada). Data are presented as mean ± standard error of the mean 
(SEM). A statistical significance level of alpha 0.05 was used for all tests. Dependent variables 
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were analyzed using a two-way analysis of variance (ANOVA) with Bonferroni’s post-hoc test, 
an unpaired t-test or an exposure-response logarithmic regression model with Tukey’s post-hoc 
test. 
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Section 3: RESULTS 
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3.1  Behavioural assessments – Aim 1 
3.1.1 Raw metrics of initial discrimination learning are not affected following MD stroke 
 Prior to set-shifting, rats were assessed to see whether they could learn a visual cue 
discrimination strategy whereby they were required to press a lever that corresponded to an 
illuminated stimulus light to receive a food reward. A two-way ANOVA determined that the 
number of trials to reach criterion was not affected by ET-1 injection status (F(1,36) = 0.5096, p 
= 0.4799) or by the number of injections given (unilateral vs. bilateral; F(1,36) = 2.835, p = 
0.1009) (Figure 3.1 A). Additionally, rats were tested 24-hours later using 20 reminder visual cue 
trials to determine whether the rats retained learning this initial visual cue rule. A two-way 
ANOVA determined that there was no significant effect of ET-1 injection status (F(1,36) = 
0.06723, p = 0.7969) or of number of injections given (F(1,36) = 0.06723, p = 0.7969) on visual 
cue strategy retention (Figure 3.1 B). 
 
3.1.2 Raw metrics of set-shifting are not affected following MD stroke 
 After successfully acquiring the visual cue strategy, rats were assessed to see whether 
they were capable of abandoning this strategy to adopt a novel spatial strategy while ignoring the 
previously relevant salient visual cues. This allowed the researcher to assess the effects of MD 
stroke on set-shifting as a measure of behavioural flexibility. A two-way ANOVA revealed no 
effect of ET-1 injection status (F(1,36) = 0.02409, p = 0.8775) or number of injections (F(1,36) = 
1.18, p = 0.2845) on trials to criterion when shifting to the response discrimination strategy 
(Figure 3.2 A). Additionally, it was determined that there was no significant effect of ET-1 
injection status (F(1,36) = 0.06581, p = 0.7990) or number of injections (F(1,36) = 2.214, p = 
0.1455) in the total number of errors to criterion in this task (Figure 3.2 B). 
 42 
 
 43 
 
 
 44 
3.1.3 Error profile suggests mild impairment behavioural flexibility following MD stroke 
  The errors that occurred during RD were further assessed by analyzing perseverative, 
regressive and never-reinforced errors. Analysis of these error types would provide insight into a 
rat’s ability to abandon a previously successful strategy that no longer provides reward 
(perseverative errors), how it is able to adopt a new strategy in response to new reward 
contingencies (regressive errors), and the types of guesses made in strategy exploration (NREs).  
 In assessing regressive errors, a two-way ANOVA revealed a non-significant effect of 
number of injection (F(1,36) = 0.2844, p = 0.5971). Additionally, there was a non-significant 
effect of ET-1injection status (F(1,36) = 2.443, p = 0.1268), however, Bonferroni’s post-hoc test 
identified that unilateral ET-1-injected rats had a significantly greater number of regressive 
errors (18.6 ± 3.2 errors) than unilateral saline-injected rats (9.4 ± 2.8 errors) (t(36) = 2.393, p = 
0.0441) (Figure 3.3 A). No significant differences were observed when assessing bilateral saline 
and bilateral ET-1 groups. 
While examining perseverative errors, a two-way ANOVA revealed a non-significant 
relationship between group condition and number of errors where no significant effect was 
identified for ET-1 injection status (F(1,36) = 0.3164, p = 0.5772) or number of injections 
(F(1,36) = 0.6066, p = 0.4411) (Figure 8B). A similar finding was observed when assessing 
NREs, where two-way ANOVA revealed no significant effect of ET-1 injection status (F(1,36) = 
0.2221, p = 0.6403) or number of injections (F(1,36) = 2.345, p = 0.1344) (Figure 3.3 C). 
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3.1.4 Modelling logistic regression of incongruent trial error rates following MD stroke 
 To better represent the relationship between the timing of errors, as well as the timing and 
efficiency of strategy change, we applied an exposure-response logistic regression model using 
the mean error rate of each group during each incongruent trial 116. An incongruent trial was 
defined as a trial in the response discrimination task where the light was illuminated above the 
incorrect lever for that rat 159. Thus, to receive a food reward the rat must be following the new 
location-based strategy. Two measures were taken from the data provided by this regression: (1) 
the IC50 defined as the number of incongruent trials at which the group is at 50% strategy 
change, and (2) the hillslope which is defined as the slope of the curve and used to measure 
group efficiency of strategy change. Using this model, it was determined that the hillslope did 
not significantly differ between groups (F(3,224) = 0.9412, p = 0.4215) (Figure 3.4 C). However, 
a significant difference between groups was identified for the IC50 (F(3,224) = 0.9412, p = 
0.0200), and Tukey post-hoc analysis revealed that bilateral-ET-1 rats had a significantly lower 
IC50 (27.5 ± 2.9) than bilateral-saline rats (38.9 ± 3.8) (F(1,36) = 7.207, p = 0.0183) (Figure 3.4 
C). 
 
3.2 Histochemistry and immunohistochemistry – Aim 1 
3.2.1 Thionin, NeuN and OX-6 analysis of ET-1 injection site(s) 
Thionin histochemistry was used to assess cell loss as a result of MD stroke injury by 
staining for cellular nissl substance. Successful injection location was determined by comparing 
areas of cell loss to stereotaxic coordinates using a rat brain atlas 162. Injection location was 
further validated by assessing neuronal nuclei (NeuN) neuronal loss and OX-6 immunoreactivity 
at the injection site(s) (Figure 3.5). 
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3.2.2 No group difference in microgliosis or astrogliosis in the corpus callosum following 
MD stroke 
 Microgliosis and astrogliosis were assessed in the CC, a major white matter tract, 
following injection of unilateral or bilateral ET-1 or saline by analyzing immunoreactivity of the 
markers OX-6 (activated microglia) and GFAP (astrogliosis). Three separate coronal sections per 
rat brain per stain were used to assess % coverage of both markers. Values from each section 
were combined and averaged to give one value of total CC coverage. A two-way ANOVA to 
assess OX-6 immunoreactivity in the CC identified that was no significant effect of ET-1 
injection status (F(1,36) = 0.5156, p = 0.4773) or number of injections (F(1,36) = 2.289, p = 
1390) on % OX-6 coverage (Figure 3.6 I). Moreover, a two-way ANOVA to assess GFAP 
immunoreactivity in the CC also identified no significant effect of ET-1 injection status (F(1,36) 
= 1.198, p = 0.2812) or numbers of injections (F(1,36) = 0.01551, p = 0.9016) on % GFAP 
coverage (Figure 3.6 J). 
 
3.2.3 No group difference in microgliosis or astrogliosis in forceps minor following MD 
stroke 
Microgliosis and astrogliosis were additionally assessed in the forceps minor following 
injection of unilateral or bilateral ET-1 or saline in the MD. One coronal section per rat brain per 
stain was used to assess % coverage of each marker, and values obtained for both left and right 
forceps minor were combined and averaged to produce one value of total forceps minor 
coverage. A two-way ANOVA assessing OX-6 immunoreactivity in the forceps minor revealed 
no significant effect of ET-1 injection status (F(1,36) = 0.1931, p = 0.6630) or number of 
injections (F(1,36) = 2.052, p = 0.1608) on % OX-6 coverage (Figure 3.7 I). Additionally, a two- 
 50 
 
 51 
 
 52 
way ANOVA assessing GFAP immunoreactivity also revealed no significant effect of ET-1 
injection status (F(1,36) = 0.4978, p = 0.4850) or number of injections (F(1,36) = 2.881, p = 
0.0983) on % GFAP coverage (Figure 3.7 J). 
 
3.2.4 No neuronal loss in PFC or NAc following MD stroke 
 Neuronal cell bodies were counted in the PFC and NAc following unilateral or bilateral 
injection of ET-1 or saline by analyzing immunoreactivity of a marker for NeuN. The PFC and 
NAc were chosen because of their reciprocal white matter connections with the MD and 
involvement in behavioural flexibility-mediating circuitry. One coronal section per rat brain per 
area of interest were used to assess the number of NeuN immunoreactive neurons. A two-way 
ANOVA to assess the number of immunoreactive neurons in the PFC revealed no effect of ET-1 
injection status (F(1,36) = 0.3023, p = 0.5858) or number of injections (F(1,36) = 0.07112, p = 
0.7912) on the number of neurons present (Figure 3.8 I). Furthermore, a second two-way 
ANOVA to assess immunoreactive cells in the NAc also identified no effect of ET-1 injection 
status (F(1,36) = 0.03667, p = 0.8492) or number of injections (F(1,36) = 0.0008, p = 0.9772) on 
the number of neurons (Figure 3.8 J). 
 
3.3 Behavioural assessments – Aim 2 
3.3.1 Initial discrimination learning not affected but memory for initial strategy slightly 
impaired following LPS injections 
As mentioned previously, prior to set-shifting, rats were assessed to see whether they 
could learn a visual cue discrimination strategy where they were required to press a lever that  
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corresponded to an illuminated stimulus light in order to receive a food reward. It was found that 
the number of trials to reach criterion in this task was not significantly different between LPS 
and saline-injected rats (t(18) = 1.243, p = 0.2298) (Figure 3.9 A). When rats were tested 24-
hours later with 20 visual cue reminder trials for memory of the visual cue strategy, an unpaired 
t-test determined that there was a significant decrease (t(18) = 2.233, p = 0.0385) in % trials 
correct in LPS-injected rats (89.0% ± 2.5%) compared to saline-injected rats (95.5% ± 1.6%) 
(Figure 3.9 B). 
 
3.3.2 Raw metrics of set-shifting are not affected following LPS injections 
 As mentioned previously, following successful completion of the visual cue task, rats 
were assessed to see whether they could adopt a novel spatial strategy while abandoning the 
initially rewarding visual cue strategy and ignoring the salient visual cues. This allowed the 
analysis of LPS injections on set-shifting as a measure of behavioural flexibility. An unpaired t-
test revealed no effect of LPS injection on trials to criterion when shifting to the response 
discrimination strategy (t(18) = 0.8352, p = 0.4146) (Figure 3.10 A). Additionally, it was 
determined that there was no significant difference between the two groups in the total number 
of errors to criterion in this task (t(18) = 0.0912, p = 3846(Figure 3.10 B). 
 
3.3.3 Error profile suggests no impairment in behavioural flexibility following LPS 
injections 
 As described previously, the individual error types from RD were assessed to examine 
issues associated with novel strategy acquisition (perseverative), strategy maintenance  
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(regressive) and ability to eliminate inappropriate strategies (NRE). Unpaired t-tests determined 
that there were no significant differences between LPS and saline-injected rats in regressive 
(t(18) = 0.7688, p = 0.4520), perseverative (t(18) = 1.889, p = 0.0751) or never-reinforced errors 
(t(18) = 0.9432, p = 0.3581) (Figure 3.11). 
 
3.3.4 Modelling logistic regression of incongruent trial error rates following LPS 
injections 
As described in the aforementioned section, an exposure-response logarithmic regression 
model was also applied to assess timing and efficiency of strategy change following LPS 
injections. Using this logarithmic regression it was determined that there was no difference 
between groups in the IC50 (t(18) = 0.5503, p = 0.5889) (Figure 3.12 B). However, it was 
determined that there was a significant difference between groups in hillslope (t(18) = 2.107, p = 
0.0495) where hillslope was significantly steeper for saline-injected rats (7.5 ± 1.4) compared to 
LPS-injected rats (4.1 ± 0.8) (Figure 3.12 C) indicating that both groups were successfully able 
to switch to the novel strategy, however, LPS-injected rats switched significantly less-efficiently. 
 
3.3.5 Spatial navigation and memory not affected following LPS injections 
 Prior to set-shifting, rats were assessed using the MWM to test whether focal injections 
of LPS resulted in learning and memory impairments. There were no significant differences in 
latency to platform location between saline and LPS injected rats (t(18) = 1.316), p = 0.2047) 
(Figure 3.13). Additionally, when rats were tested for retention of the platform region location  
 58 
 
 59 
 
 
 
 
 
 60 
 
 
 
 
 
 
 
 
 
 
 61 
24-hours following training there was no significant difference between groups (t(18) = 0.9447, 
p = 0.3573) (Figure 3.13). 
 
3.4 Histochemistry and immunohistochemistry – Aim 2 
3.4.1 LPS rats had significantly increased microgliosis and astrogliosis in corpus callosum 
 Microgliosis and astrogliosis were assessed in the CC using three separate coronal 
sections per rat brain per stain to assess % coverage of both markers. Values from each section 
were combined and averaged to give one value of total CC coverage. An unpaired t-test to assess 
OX-6 positive activated microglia in the CC demonstrated a significant increase (t(17) = 20.78, p 
< 0.0001) in activated microglia in LPS-injected rats (57.8% ± 2.5%) compared to saline-injected 
rats (1.6% ± 0.4%) (Figure 3.14 E). Additionally, an unpaired t-test to assess GFAP 
immunoreactivity in the CC also identified a significant increase (t(17) = 2.942, p = 0.0091) in 
GFAP immunoreactivity in LPS-injected rats (45.5% ± 2.3%) compared to saline-injected rats 
(32.1% ± 4.0%) (Figure 3.14 F). 
 
3.4.2 LPS rats had significantly increased microgliosis but not astrogliosis in forceps 
minor 
 Microgliosis and astrogliosis were additionally assessed in the forceps minor following 
bilateral injection of LPS or saline in the MD. One coronal section per rat brain per stain was 
used to assess % coverage of each marker, and values obtained for both left and right forceps 
minor were combined and averaged to produce one value of total forceps minor coverage. An 
unpaired t-test assessing OX-6 immunoreactivity in the forceps minor revealed a significant  
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increase (t(17) = 11.89, p < 0.0001) in activated microglia in LPS-injected rats (70.5% ± 5.6%) 
compared to saline-injected rats (0.3% ± 0.1%) (Figure 3.15 E). Alternatively, an unpaired t-test 
assessing GFAP immunoreactivity revealed no significant difference between groups in % 
forceps minor coverage (t(18) = 1.868, p = 0.0791) (Figure 3.15 F). 
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Section 4: DISCUSSION 
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4.1 Unilateral MD stroke rats displayed mild behavioural inflexibility in the form of a 
regressive phenotype 
 The first aim of this study was to determine if focal MD stroke could lead to behavioural 
inflexibility, a form of ED in rats. Prior to assessing behavioural flexibility, rats were first trained 
in a visual cue discrimination strategy, followed by testing memory of this strategy the following 
day. As expected, there were no differences between experimental groups in completing either of 
these tasks, demonstrating that learning and memory were intact in all groups and behavioural 
flexibility could be reliably assessed using the set-shifting task.  
Initially we had predicted a perseverative phenotype following MD stroke based on the 
findings from pharmacological inactivation studies where inactivation of the MD led to increased 
perseverative errors, presumably because of dysfunctional circuitry between the MD and PFC 
118. This effect was not seen in our study as there were no behavioural changes observed 
following bilateral stroke, however, we did identify a significant regressive behavioural 
phenotype following unilateral MD stroke. Interestingly, this is similar to the error profile 
observed following stroke induced in the dorsal striatum, another subcortical structure that is 
highly involved in this behavioural flexibility mediated circuitry 116.  
Previous experimental work outlining the effects of MD lesions and or transient 
inactivation on executive function has produced conflicting findings, perhaps due to the varying 
methodologies. For example, one study identified that rats had increased perseveration in a 
strategy set-shifting t-maze task following bilateral pharmacological inactivation of the MD 118. 
Conversely, in one study assessing the effects on bilateral MD stroke using a digging task of 
behavioural flexibility, no impairment was identified following MD stroke 163. Alternatively, an 
additional study examining the effects of unilateral MD stroke found that in this same task rats 
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were impaired and required a greater number of trials to reach criterion, however, no 
perseverative phenotype was identified 164. This ambiguity in experimental findings following 
MD damage was also reflected in the findings of this study. In our study, it was seen that there 
was no difference in trials to criterion or total errors during the response discrimination task, 
however, when the error profile was broken into the three discrete error types, a significant 
regressive behavioural phenotype was identified. Using this task to assess behavioural flexibility 
allowed us to identify subtle differences in cognition that may not have been identified using 
other tests of ED that assess only traditional indices such as ability to complete the task, trials to 
criterion, total errors, etc. This is one possible explanation for the prior studies that found no 
effect of MD inactivation on executive function. In addition to assessing the error profile of rats 
during set-shifting, we also applied an exposure-response logarithmic regression model to the 
group error rate of the 4 experimental groups. The curve obtained from this analysis allowed us 
to assess subtle changes that occur in group behaviour by examining the temporal dynamics of 
strategy change. A significant group effect was identified for the IC50, which is a measure of the 
number of incongruent trials to 50% strategy change. Bilateral stroke rats reached 50% strategy 
change sooner than their saline control, suggesting that they were learning to respond to different 
reward contingencies quicker than controls. However, they did not reach criterion quicker than 
controls suggesting that while they were able to effectively abandon the unsuccessful visual cue 
strategy, they could not reliably adopt the novel location-based strategy quicker than controls. It 
is important to note that most work has focused on pharmacological inactivation or neurotoxic 
lesion of the MD, with only a few studies investigating the role of the MD post-stroke. A stroke 
involves several other factors in addition to a MD lesion that need to be considered including 
recruitment of glia and immune cells, white matter integrity, possible axonal degradation, etc. 
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Moreover, pharmacological inactivation produces transient effects whereby a structure is 
inactivated for a short period of time, whereas stroke induces chronic changes that involve 
different phases of inflammation and healing. The findings of the studies discussed herein, in 
addition to the findings of this thesis identifying a regressive behavioural phenotype following 
unilateral MD stroke, all provide evidence for a complexity with respect to the role and function 
of the MD in mediating executive function. While it’s circuitry has been well-defined, the 
practical consequences of MD damage are diverse and further work needs to be completed to 
delineate the role that it is playing in cognitive impairment. 
 
4.2 MD stroke rats did not display WMI or cell loss in areas of connected circuitry 
mediating behavioural flexibility 
 Rat brains were assessed using markers for activated microglia and reactive astrocytes, 
which are major components of the inflammatory process post-stroke. This was completed in the 
forceps minor and the CC, two major white matter structures, due to the strong relationship 
previously observed between WMI and cognitive impairment84,94,95,99. We had predicted that the 
behavioural phenotype observed in the unilateral MD stroke rats could be explained by increased 
WMI. In the present study, this was not observed, as there was no significant inflammation 
generated in either of these structures. The lack of WMI seen in this study was also seen in a 
similar study performed by Cordova et al. 163, where an MD stroke was performed on similarly 
aged (3- to 5-month-old) rats. A later study164 by the same group found that performing the same 
stroke in an older (12-month-old) rat could elicit the expected WMI and ED. Additionally, 
neuron cell number was assessed in two areas with extensive connections with the MD that 
mediate behavioural flexibility to determine if the regressive behavioural phenotype was due to 
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neuron loss. It was determined that there was no difference in the number of neurons present in 
the PFC or NAc between MD stroke and control rats. Therefore, the observed behavioural 
phenotype cannot be explained by neuron loss. Although the expected inflammation and damage 
was not seen in our stroke model, similar studies support these results and suggest that age may 
be largely contributing to the limited pathological response to this type of stroke.  
Previous studies have outlined the enhanced susceptibility of the older brain to stroke and 
some of the underlying cellular mechanisms behind this phenomenon. This includes evidence 
that older rodents show greater impairment and less recovery from stroke, greater infarct size and 
neuronal death and greater cytoproliferative activity in astrocytes and macrophages 165. 
Furthermore, some studies comparing old and young rats following MCAO showed that 
sensorimotor function and coordination had recovered in young rats before 14 days post-stroke, 
but the recovery of the old rats plateaued at 70-85% by 14 days 166. Other research has shown 
similar findings and additionally noted a greater decrease in damage and neuroinflammatory 
markers by 14 days post-stroke in young rats 167,168. Thus, it is possible that the enhanced 
resilience of young rats to stroke may be protective against persistent white matter inflammation 
and neurodegeneration. 
 
4.3 LPS-injected rats displayed mild impairment in behavioural flexibility in addition 
to significant WMI 
 The second aim of this thesis was to determine whether inducing WMI alone could be 
sufficient to initiate ED in the rat. Preliminary data from our research group demonstrated that 
inflammation in frontal white matter structures such as the corpus collosum following a striatal 
stroke was associated with ED in the form of a regressive behavioural phenotype (unpublished 
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data). Based on these findings, this study looked at the effects of focal injections of LPS into the 
CC on behavioural flexibility. We had predicted that inducing WMI in the CC would produce 
behavioural inflexibility in the form of a regressive behavioural phenotype. As demonstrated by 
the completion of the visual cue task where there was no difference between groups in the 
number of trials to reach criterion indicating that LPS-injected rats demonstrated no impairments 
in learning. While there was a significant difference between groups in memory for the visual 
cue strategy the following day, LPS-injected rats still performed at a group rate of 89% of trials 
correct. Additionally, since there was no difference between groups in the MWM memory 
assessment, we were confident that set-shifting would be an accurate assessment of behavioural 
flexibility in these rats. 
 During the response discrimination task, there were no significant differences between 
groups in the trials to criterion or total errors in completing the task. Additionally, when 
assessing the complete error profile, there were no difference found between groups regarding 
the individual error types. Although non-significant, the individual error types in the set-shifting 
task demonstrated that LPS-injected rats had decreased perseverative errors as well as increased 
regressive errors. Interestingly, this is the same pattern of errors observed following unilateral 
striatal stroke 116, and unilateral MD stroke, as observed in the first aim of this thesis. Given the 
significant inflammation that was induced within the CC, we had expected to see a robust 
behavioural response, given the strong correlation identified between frontal white matter 
inflammation and behavioural inflexibility. While a non-significant error profile was observed, 
ED in the LPS-injected rats was highlighted by the results seen following the application of an 
exposure-response logarithmic regression model to the group error rate of LPS and control rats. 
When assessing hillslope, which is a measure of strategy change efficiency, it was found that 
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control rats had a significantly steeper slope than LPS-injected rats. The point at which 50% 
strategy change was reached, however, occurred at approximately the same time. These findings 
indicate that while both groups were able to complete the task and to switch strategies in the 
same amount of trials, the LPS-injected rats switched strategies with less efficiently. LPS-
injected rats abandoned the visual cue strategy sooner as indicated by the earlier decline in the 
curve, however, it took them longer to identify and maintain the appropriate strategy as indicated 
by the flatter slope and the corresponding increase in regressive errors. In comparison, saline-
injected rats took slightly longer to abandon the initial visual cue strategy, however, once they 
did they very quickly adopted the novel location-based strategy and maintained this strategy 
successfully as indicated by the steep slope of the curve. This significant decrease in hillslope 
was also observed following dorsal striatal stroke in aged rats 116. While the error profile 
differences were not significant, the findings from this model suggest that there are differences in 
behavioural flexibility between LPS rats and controls, they may just require more sensitive 
metrics to tease apart these differences. 
 When assessing pathological differences between LPS rats and controls, it was evident 
that focal injection of LPS successfully induced WMI in frontal white matter structures as 
indicated by a significant increase in microglia in the corpus collosum and forceps minor, as well 
as significant astrogliosis in the CC. Although WMI has been identified as a strong correlate of 
behavioural inflexibility, this significant amount of WMI did not produce as robust behavioural 
phenotype as we had expected. It is possible that the inflammation seen may not be sufficient to 
cause cognitive impairment within the time-frame utilized in this study. While a 28-day 
timepoint was sufficient to identify behavioural inflexibility following MD stroke as seen in the 
first aim of this thesis, WMI alone may take longer to produce an observable behavioural 
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phenotype. Following a stroke, there is immediate cell death that occurs at the infarct site as well 
as additional cell damage in the penumbra that surrounds the central core of the infarct. The 
extent of cell death following the initial stroke depends greatly upon the inflammatory processes 
that are initiated by this hypoxic event. Alternatively, with focal injection of LPS, the 
inflammatory process begins with the recruitment of microglia and production of inflammatory 
cytokines and this may require a longer time period than 28-days to produce cell death or 
damage on the level that would occur following stroke. Thus, WMI inflammation may require 
longer periods of time to cause deficits or young may be more resilient to WMI than older rats 
overall, explaining why a robust behavioural phenotype was not observed following focal LPS 
injections.  
 
4.4 Caveats and future directions 
An important caveat in these studies was only being able to assess pathology 28 days post-
stroke. With the extensive behavioural testing that was completed, we had to be sure that the rats 
recovered fully from their surgeries before testing began to ensure that there were no 
confounding factors that could affect behaviour in the set-shifting task such as pain or discomfort 
from wound healing. It would, however, be valuable to include additional rats in the cohort to be 
sacrificed at different time points beyond the initial 28-day period before sacrifice to get a clearer 
picture of the pathophysiological changes occurring throughout time.  
While a significant regressive behavioural phenotype was observed following unilateral MD 
stroke, no significant pathological changes were identified in these rats using markers for 
activated microglia, astrocytosis or neurons. As mentioned previously, due to the young age of 
these rats, it is possible WMI was transiently present. However, further work must consider the 
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possibility that damaging effects of the inflammatory process may have compromised white 
matter integrity that was not visible with the histology completed in this study. Further 
immunohistological analyses using markers for myelin basic protein (MBP) or degenerating 
myelin basic protein (dMBP), or histological analyses such as luxol fast blue to assess white 
matter integrity would provide clarification regarding damage that may have occurred to the 
white matter following MD stroke. Moreover, it would be valuable to assess possible axonal 
degeneration, as in a previous study of MD stroke it was identified that while no lasting WMI 
was observed, axonal degeneration was identified along thalamocortical projections 92. An 
additional caveat in this study is that only the effects of bilateral MD stroke and unilateral stroke 
in the right MD were considered. Since unilateral stroke in the right MD produced behavioural 
inflexibility but no effects were seen following bilateral MD stroke, it is necessary for future 
work to consider the effects of unilateral stroke on the left MD only. It is possible that 
behavioural consequences following left MD stroke could be antagonistic to the behavioural 
phenotype following right MD stroke resulting in no phenotype being observed following 
bilateral MD stroke. To our knowledge, no studies have considered the differential effects of 
unilateral stroke in the right MD compared to the left MD, and these findings would have 
important consequences for future studies of MD stroke. Moreover, the effects of MD stroke 
should be further investigated in older rats involving a wide variety of histological analyses to 
assess WMI, neuronal loss and white matter integrity to observe how these factors can change 
with age. 
Finally, the second aim of this thesis, to our knowledge, was the first investigation of the 
effects of focally-induced WMI on cognition. These initial findings demonstrating that WMI 
alone may have subtle effects on behaviour in young rats in addition to the prior clinical and 
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experimental work relating WMI to cognitive impairment imply that more work is needed to be 
completed to understand the complex role of WMI. Since the rats used in this study were only 6-
months-old, future work should examine the effects of focally-inducing WMI in middle to older 
age rats to assess how the inflammatory profile and behavioural consequences of inflammation 
change with age and with the differing levels of basal WMI that exist in these older rats. 
Additionally, combining focal LPS injections into the white matter with the induction of 
subcortical stroke would provide a valuable model to examine how increased levels of WMI can 
affect stroke pathophysiology and subsequent cognitive impairment. Moreover, the effects of 
focally-induced WMI should be explored in a chronic manner, either with multiple focal 
injections of LPS over time or one injection followed by a lengthy survival time period. Finally, 
while significant correlations have been identified between CC WMI and behavioural 
inflexibility, there is also diffuse WMI throughout many additional white matter tracts. Thus, it is 
possible that only inducing inflammation in the CC may be insufficient to produce a robust 
behavioural phenotype. It would be valuable to determine the effects of focally-inducing 
inflammation in a variety of white matter tracts in the same model to see how this effects ED. 
Therefore, allowing WMI to persist for a longer period of time or inducing WMI in a variety of 
white matter structures may allow for the necessary damaging effects to occur to produce robust 
behavioural dysfunction. 
 
 
 
 
 
 
 75 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section 5: SUMMARY AND CONCLUSIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 76 
 The objective of the first aim of this thesis was to determine whether MD stroke would 
result in WMI and impairments in behavioural flexibility. It was determined that rats receiving a 
unilateral MD stroke had a regressive behavioural phenotype, however, this was not paired with 
inflammation in major white matter structures such as the CC and forceps minor. Additionally, 
there was no neuronal loss identified in structures connected to the MD that mediate components 
of behavioural flexibility such as the PFC and NAc. The objective of the second aim of this 
thesis was to determine whether focally-inducing inflammation in the CC could produce ED in 
the form of behavioural inflexibility. While these rats did not display a significant behavioural 
phenotype when assessing traditional error profile measurements, a significant difference was 
observed in efficiency of strategy change using a logarithmic regression model. Additionally, 
LPS-injected rats had significant inflammation in the CC and forceps minor. 
 Although the circuitry of the MD has been well-defined, studies that have targeted the 
MD up to this point have found inconsistent evidence of the functional outcomes following MD 
damage or inactivation. Moreover, this body of research is especially lacking in studies 
investigating the effects of focal MD stroke on cognition. The findings from our MD stroke 
study provide additional evidence to help delineate the role the MD is playing in cognition. 
Additionally, while prior work relating WMI to ED has been strictly correlative, our second 
study provides the first evidence that inducing focal WMI may be sufficient to produce cognitive 
impairment. While much work still needs to be done to determine the complete mechanism by 
which WMI contributes to the cognitive dysfunction, this study was a necessary first step in 
investigating this mechanism and has provided valuable insight to guide future studies of WMI. 
Both of these studies provide additional evidence for the role that age plays in mediating the 
effects of stroke and inflammation. In accordance with our findings, a young age may provide 
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rats with an increased resiliency to the detrimental effects caused by stroke and WMI. Our 
studies provide valuable models to investigate the effects of MD stroke and WMI as these young 
rats have limited basal WMI. This, however, provides a need for future studies that investigate 
ischemic damage and WMI within rats of varying ages to determine age-related changes in 
behaviour and pathology in these specific models. These future studies will provide valuable 
insight to the mechanism of WMI, which may ultimately provide potential targets for future 
therapeutic interventions.  
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